Clinical trials evaluating the effects other anti-PD-1 MoAbs, such as tislelizumab (BGB-A317; BeiGene) and camrelizumab (SHR-1210, HR-301210; Jiangsu Hengrui Medicine/Incyte) as single agents are also ongoing in HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.